Clene (CLNN) director granted 1,893 stock options at $7.30
Clene Inc. (CLNN) disclosed a director stock option grant.
Rhea-AI Filing Summary
Clene Inc. (CLNN) disclosed a director stock option grant. On 11/13/2025, the director received an option for 1,893 shares of common stock at an exercise price of $7.30 per share under the Amended 2020 Stock Plan. The option vests immediately upon grant and expires on 11/12/2035.
Following the transaction, the filing shows 1,893 derivative securities beneficially owned, held in direct ownership.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 1,893 shares
Grant/Award
1 txn
Insider
Kiernan Matthew
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | stock option | 1,893 | $0.00 | $0.00 |
Holdings After Transaction:
stock option — 1,893 contracts (Direct)
Footnotes (1)
- F1. This option was granted on November 13, 2025 as an option for 1,893 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $7.30 per share. The options vest immediately upon grant.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Clene (CLNN) report in this Form 4?
A director was granted a stock option for 1,893 shares at an exercise price of $7.30 per share.
When was the stock option granted for CLNN?
The option was granted on 11/13/2025.
What is the vesting schedule of the CLNN option grant?
The option vests immediately upon grant.
When does the CLNN option expire?
The option expires on 11/12/2035.
How many derivative securities are beneficially owned after the transaction?
The filing shows 1,893 derivative securities beneficially owned.
Under which plan was the CLNN option granted?
The option was granted under the Clene Inc. Amended 2020 Stock Plan.
What is the reported ownership form for the option?
The ownership form is reported as Direct (D).
AI-generated analysis. How Rhea-AI works. Not financial advice.